ORI Capital is venture capital firm headquartered in Hong Kong. It was founded in 2015 by Simone Song, who was the Managing Director of China Healthcare at Goldman Sachs from 2010-2015. The management team of the firm is comprised of former Goldman Sachs executives and healthcare scientists. In 2017, the fund was valued at $200 million.
ORI Capital targets investment in the global healthcare technology industry. In 2016, ORI Capital invested $100 million in Kymab, a biopharmeutical company developing human anti-body based therapies.
Pillar Biosciences is a clinical cancer diagnostics company .
Cold Genesys is a privately-held, immunotherapy based biopharmaceutical company